Presentation is loading. Please wait.

Presentation is loading. Please wait.

Forest plot of (left) overall survival and (right) progression-free survival for gefitinib versus docetaxel in the INTEREST (IRESSA NSCLC Trial Evaluating.

Published byBruno Higgins Modified over 5 years ago

Similar presentations

Presentation on theme: "Forest plot of (left) overall survival and (right) progression-free survival for gefitinib versus docetaxel in the INTEREST (IRESSA NSCLC Trial Evaluating."— Presentation transcript:

1 Forest plot of (left) overall survival and (right) progression-free survival for gefitinib versus docetaxel in the INTEREST (IRESSA NSCLC Trial Evaluating Response and Survival versus Taxotere) study (pretreated setting) by clinical characteristics and epid... Forest plot of (left) overall survival and (right) progression-free survival for gefitinib versus docetaxel in the INTEREST (IRESSA NSCLC Trial Evaluating Response and Survival versus Taxotere) study (pretreated setting) by clinical characteristics and epidermal growth factor receptor (EGFR) biomarkers [37, 38]. ORR: objective response rate. #: unadjusted analysis – per-protocol population for clinical factors and intent-to-treat population for biomarker factors; ¶: adjusted analysis – evaluable for response (EFR) population; +: EFR population. A.A. Armour, and C.L. Watkins Eur Respir Rev 2010;19: ©2010 by European Respiratory Society

Download ppt "Forest plot of (left) overall survival and (right) progression-free survival for gefitinib versus docetaxel in the INTEREST (IRESSA NSCLC Trial Evaluating."

Similar presentations

IRESSA A Case Study in Personalised Medicine Dr Rose McCormack

IRESSA A Case Study in Personalised Medicine Dr Rose McCormack
Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.
IRESSA: A journey of experience from broad to biomarker populations

IRESSA: A journey of experience from broad to biomarker populations
© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey 07458 Lung Cancer and Gefitinib  Lung cancer statistics in the.

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.
J Thorac Oncol. 2012;7: 1653–1660) David P. Carbone, MD, PhD,* Keyue Ding, PhD,† Heinrich Roder, PhD,‡ Julia Grigorieva, PhD,‡ Joanna Roder, PhD,‡ Ming-Sound.

J Thorac Oncol. 2012;7: 1653–1660) David P. Carbone, MD, PhD,* Keyue Ding, PhD,† Heinrich Roder, PhD,‡ Julia Grigorieva, PhD,‡ Joanna Roder, PhD,‡ Ming-Sound.
Volume 18, Issue 6, Pages (September 2015)

Volume 18, Issue 6, Pages (September 2015)
Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Michael Lee at 2016 ASCO Annual Meeting
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Table 1 Baseline patient characteristics

Table 1 Baseline patient characteristics
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Testing algorithm integrating diagnostic and predictive analysis in nonsmall cell lung cancer (NSCLC). Testing algorithm integrating diagnostic and predictive.

Testing algorithm integrating diagnostic and predictive analysis in nonsmall cell lung cancer (NSCLC). Testing algorithm integrating diagnostic and predictive.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
FDA Reviews Approval for Iressa™

FDA Reviews Approval for Iressa™
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.
Disease progression is preceded by right ventricular remodelling, but not by changes in clinical parameters. Disease progression is preceded by right ventricular.

Disease progression is preceded by right ventricular remodelling, but not by changes in clinical parameters. Disease progression is preceded by right ventricular.
Platelet-derived growth factor receptors (PDGFRs) and ligand patterns.

Platelet-derived growth factor receptors (PDGFRs) and ligand patterns.
The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.
Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.
Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Similar presentations

Ads by Google